ALGS Logo

Aligos Therapeutics, Inc. (ALGS) 

NASDAQ$11.44
Market Cap
$41.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
437 of 924
Rank in Industry
258 of 527

ALGS Insider Trading Activity

ALGS Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00
Sells
$00

Related Transactions

No records found

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and …

Insider Activity of Aligos Therapeutics, Inc.

Over the last 12 months, insiders at Aligos Therapeutics, Inc. have bought $0 and sold $0 worth of Aligos Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aligos Therapeutics, Inc. have bought $13.13M and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 7,933,601 shares for transaction amount of $6M was made by Nuechterlein Carole () on 2023‑10‑25.

List of Insider Buy and Sell Transactions, Aligos Therapeutics, Inc.

2023-10-25PurchaseNuechterlein Carole
7.93M
22.4566%
$0.76$6M+4.10%
2020-10-20PurchaseVivo Capital VIII, LLC10 percent owner
550,000
1.9863%
$15.00$8.25M+61.44%
2020-10-20PurchaseNovo Holdings A/S10 percent owner
200,000
0.7223%
$15.00$3M+61.44%
2020-10-20PurchaseWoiwode Thomasdirector
200,000
0.7223%
$15.00$3M+61.44%
2020-10-20PurchaseVersant Venture Capital VI, L.P.director
400,000
1.4446%
$15.00$6M+61.44%
Total: 5

Insider Historical Profitability

49.97%
Nuechterlein Carole
11025941
307.3098%
$126.14M10+4.1%
Vivo Capital VIII, LLC10 percent owner
3116658
86.866%
$35.65M10+61.44%
Novo Holdings A/S10 percent owner
2614563
72.8719%
$29.91M10+61.44%
Woiwode Thomasdirector
862444
24.0376%
$9.87M10+61.44%
Versant Venture Capital VI, L.P.director
862444
24.0376%
$9.87M10+61.44%

Historical Insider Profitability vs. Competitors

$4,273,853
101
-36.67%
$40.54M
$77,062,892
41
13.96%
$38.79M
$140,938,207
36
14.75%
$43.63M
$241,165
22
-16.72%
$38.37M
$167,476,357
20
-1.54%
$41.08M

ALGS Institutional Investors: Active Positions

Increased Positions22+78.57%436,981+24.19%
Decreased Positions9-32.14%511,070-28.29%
New Positions12New265,461New
Sold Out Positions6Sold Out475,504Sold Out
Total Postitions41+46.43%2M-4.1%

ALGS Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Adage Capital Partners Gp, L.L.C.$5,483.0010.83%325,000+106,187+48.53%2024-12-31
Ecor1 Capital, Llc$4,312.008.52%255,57300%2024-12-31
Deep Track Capital, Lp$4,118.008.14%244,11000%2024-12-31
Vivo Capital, Llc$2,393.004.73%141,87900%2024-12-31
Altitude Crest Partners Inc.$1,920.003.79%113,78700%2024-03-31
Vanguard Group Inc$1,632.003.23%96,762+32,948+51.63%2024-12-31
Baker Bros. Advisors Lp$1,401.002.77%83,05500%2024-12-31
Hhlr Advisors, Ltd.$1,286.002.54%76,24700%2024-12-31
Trexquant Investment Lp$1,165.002.3%69,050+69,050New2024-12-31
Ikarian Capital, Llc$1,085.002.14%64,300+64,300New2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.